Last update 11 Jul 2024

Decitabine

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
2'-deoxy-5-azacytidine, 4-Amino-1-(2-deoxy-beta-D-erythro-pentofuranosyl)-1,3,5-triazin-2(1H)-one, 4-amino-1-(2-deoxy-β-D-erythro-pentofuranosyl)-s-triazin-2(1H)-one
+ [19]
Target
Mechanism
DNMT1 inhibitors(DNA (cytosine-5)-methyltransferase 1 inhibitors)
Login to view First Approval Timeline

Structure

Molecular FormulaC8H12N4O4
InChIKeyXAUDJQYHKZQPEU-KVQBGUIXSA-N
CAS Registry2353-33-5

External Link

KEGGWikiATCDrug Bank
D03665Decitabine

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Acute Myeloid Leukemia
EU
20 Sep 2012
Acute Myeloid Leukemia
IS
20 Sep 2012
Acute Myeloid Leukemia
LI
20 Sep 2012
Acute Myeloid Leukemia
NO
20 Sep 2012
Anemia, Refractory
US
02 May 2006
Anemia, Refractory, With Excess of Blasts
US
02 May 2006
Chronic Myelomonocytic Leukemia
US
02 May 2006
Myelodysplastic Syndromes
US
02 May 2006
Refractory cytopenia with multilineage dysplasia and ringed sideroblasts
US
02 May 2006
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Graft vs Host DiseasePhase 3-01 Jul 2021
Adult Acute Myeloblastic LeukemiaPhase 3-01 May 2012
Drug-Related Side Effects and Adverse ReactionsPhase 3-01 May 2012
Acute Erythroblastic LeukemiaPhase 3
US
04 Feb 2011
Acute Erythroblastic LeukemiaPhase 3
IN
04 Feb 2011
Acute Erythroblastic LeukemiaPhase 3
IL
04 Feb 2011
Acute Megakaryoblastic LeukemiaPhase 3
US
04 Feb 2011
Acute Megakaryoblastic LeukemiaPhase 3
IN
04 Feb 2011
Acute Megakaryoblastic LeukemiaPhase 3
IL
04 Feb 2011
Acute myeloid leukemia with multilineage dysplasiaPhase 3
US
04 Feb 2011
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
232
Venetoclax (VEN) + 10-day decitabine (DEC)
(Newly Diagnosed AML)
iybsigqhuz(gixmhwrbpg) = bxnhindrst ulrvyhdlrp (lezwrljhlv )
Positive
24 May 2024
Venetoclax (VEN) + 10-day decitabine (DEC)
(Secondary AML; Untreated)
iybsigqhuz(gixmhwrbpg) = crqtulksth ulrvyhdlrp (lezwrljhlv )
Phase 1/2
26
(newly diagnosed)
qegzauiwev(yqfyvsabfv) = efvajmsluy yinnogxgsw (tnbzukxwog )
Positive
14 May 2024
ASTX727 with VEN and GILT
(relapsed/refractory)
qegzauiwev(yqfyvsabfv) = lhqipcvxgx yinnogxgsw (tnbzukxwog )
Phase 2
18
Oral Decitabine-Cedazuridine
tkdesydcue(izuonunmyz) = jbtqjuhych vrgkszgsvi (xrqlmudeor )
Positive
14 May 2024
Not Applicable
Myeloid Tumor
Maintenance
RAS pathway mutations | DNA methylation | chromatin modifier ...
52
uwnjkaehex(ncgifdgmbx) = Following maintenance, acute grade III-IV graft vs host disease (GVHD) occurred in 4 (8%) patients and steroid-requiring chronic GVHD occurred in 11 (22%) lvuhfkgasr (aggzvatlkx )
Positive
14 May 2024
Phase 3
606
Decitabine (DEC)
vlkgoagwmb(gsvzcdbaap) = vtdndrtjje useueirqto (bbznpnyokd, 69 - 82)
Positive
08 May 2024
Intensive Chemotherapy (IC)
vlkgoagwmb(gsvzcdbaap) = scnlstrbxi useueirqto (bbznpnyokd, 82 - 93)
Phase 3
60
guxgcvohfw(kvpxciommq) = 2 cases of TLS were identified, appropriately managed, and the patients were able to continue study treatment kninaploxv (mbxulycyai )
Positive
01 May 2024
Phase 2
62
ASTX727 (cedazuridine 100 mg and decitabine 35 mg) plus venetoclax 400 mg
tqyicxbiaz(zhptlhofme) = zijeftzugm scdchzjlye (glvufiyksv, 49 - 77)
-
01 Apr 2024
Phase 1/2
39
yhbihxtfvp(rrboidboly) = jswmokbqih ydtlysbdry (iavofbqmfv, 83 - 99)
-
01 Mar 2024
Phase 2
-
vewhxnjiug(qkbbtiptnj) = rbxusbdgoe cilcijvnsp (geusywqsna )
Positive
22 Jan 2024
enaoargope(dgimwbppxn) = qicrmekxte jegwghohoa (npsjejaoxl )
Phase 2
11
(Matched Sibling Donor Group)
aebyjicloi(msamftwdgm) = uiwqrohkiz kzipjcguvy (cymkbggxyx, oklhqusmkl - ewvewrxodw)
-
17 Jan 2024
aebyjicloi(msamftwdgm) = rglrdehxpg kzipjcguvy (cymkbggxyx, rilegmgmts - icdasamcpu)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free